| ŘIHÁČKOVÁ, Eva, Michal ŘIHÁČEK, Mária VYSKOČILOVÁ, Dalibor VALÍK a Lubomír ELBL. Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma-a review and prospects for the future. Frontiers in Cardiovascular Medicine. Lausanne: Frontiers, 2023, roč. 10, August 2023, s. 1-16. ISSN 2297-055X. Dostupné z: https://dx.doi.org/10.3389/fcvm.2023.1243531. |
Další formáty:
BibTeX
LaTeX
RIS
@article{2307377,
author = {Řiháčková, Eva and Řiháček, Michal and Vyskočilová, Mária and Valík, Dalibor and Elbl, Lubomír},
article_location = {Lausanne},
article_number = {August 2023},
doi = {http://dx.doi.org/10.3389/fcvm.2023.1243531},
keywords = {lymphoma; cardiotoxicity; chemotherapy; modern treatment; prevention; cardiac adverse events},
language = {eng},
issn = {2297-055X},
journal = {Frontiers in Cardiovascular Medicine},
title = {Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma-a review and prospects for the future},
url = {https://www.frontiersin.org/articles/10.3389/fcvm.2023.1243531/full},
volume = {10},
year = {2023}
}
TY - JOUR
ID - 2307377
AU - Řiháčková, Eva - Řiháček, Michal - Vyskočilová, Mária - Valík, Dalibor - Elbl, Lubomír
PY - 2023
TI - Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma-a review and prospects for the future
JF - Frontiers in Cardiovascular Medicine
VL - 10
IS - August 2023
SP - 1-16
EP - 1-16
PB - Frontiers
SN - 2297055X
KW - lymphoma
KW - cardiotoxicity
KW - chemotherapy
KW - modern treatment
KW - prevention
KW - cardiac adverse events
UR - https://www.frontiersin.org/articles/10.3389/fcvm.2023.1243531/full
N2 - Treatment of malignant lymphoma has for years been represented by many cardiotoxic agents especially anthracyclines, cyclophosphamide, and thoracic irradiation. Although they are in clinical practice for decades, the precise mechanism of cardiotoxicity and effective prevention is still part of the research. At this article we discuss most routinely used anti-cancer drugs in chemotherapeutic regiments for malignant lymphoma with the focus on novel insight on molecular mechanisms of cardiotoxicity. Understanding toxicity at molecular levels may unveil possible targets of cardioprotective supportive therapy or optimization of current therapeutic protocols. Additionally, we review novel specific targeted therapy and its challenges in cardio-oncology.
ER -
ŘIHÁČKOVÁ, Eva, Michal ŘIHÁČEK, Mária VYSKOČILOVÁ, Dalibor VALÍK a Lubomír ELBL. Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma-a review and prospects for the future. \textit{Frontiers in Cardiovascular Medicine}. Lausanne: Frontiers, 2023, roč.~10, August 2023, s.~1-16. ISSN~2297-055X. Dostupné z: https://dx.doi.org/10.3389/fcvm.2023.1243531.
|
